{"data":{"id":"us/21-cfr-516.2106","jurisdiction":"us","citation":"21 CFR 516.2106","heading":"Sirolimus.","body":"(a) Specifications. Each sustained-release tablet contains 0.4, 1.2, or 2.4 milligrams (mg) sirolimus.\n(b) Sponsor. See No. 086169 in § 510.600(c) of this chapter.\n(c) Conditions of use in cats—(1) Amount. Administer orally once weekly at a dose of 0.3 mg/kilogram of bodyweight.\n(2) Indications for use. For the management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy (HCM).\n(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal law to use this product other than as directed in the labeling.","path":["Title 21—Food and Drugs","CHAPTER I—FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES","SUBCHAPTER E—ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS","PART 516—NEW ANIMAL DRUGS FOR MINOR USE AND MINOR SPECIES","Subpart E—Conditionally Approved New Animal Drugs For Minor Use and Minor Species"],"source_url":"https://www.ecfr.gov/api/versioner/v1/full/2026-08-25/title-21.xml","current_through":"2026-08-25","vintage":"","retrieved_at":"2026-08-27T02:24:47Z","sha256":"a6e23e71ae66677d8c395be32c2440536febe56f1fc3e30603cd3e33da5a3ec3","source_id":"us-cfr","stale":true,"prev":"us/21-cfr-516.1780","next":"us/21-cfr-516.2475"},"notice":"GroundRules: Original legal text. Not legal advice."}